Tropical infections caused by Staphylococcus aureus

Similar documents
Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust

Skin & Soft Tissue Infections (SSTI) Skin & Soft Tissue Infections. Skin & Soft Tissue Infections (SSTI)

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know

Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections

Methicillin-Resistant Staphylococcus aureus

MRSA Outbreak in Firefighters

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

Infections caused by Methicillin-Resistant Staphylococcus

Ca-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007

5/17/2012 DISCLOSURES OBJECTIVES CONTEMPORARY PEDIATRICS

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Mrsa abscess and cellulitis

S aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Prevalence & Risk Factors For MRSA. For Vets

Disclosures. Consider This Case. Objectives. Consequences of Bites. Animal Bites: What to Do and What to Avoid. Animal Bites: Epidemiology

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

M R S A. Methicillin-Resistant Staphylococcus aureus. The Facts

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally

Source: Portland State University Population Research Center (

Risk factors? Insect bites? Hygiene? Household crowding Health literacy

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die

Rational management of community acquired infections

Central Nervous System Infections

Overview Management of Skin and Soft Tissue Infections in the MRSA Era

Replaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals

CHAPTER 18 THE COCCI OF MEDICAL IMPORTANCE. Learning Objectives

22/09/2010. Laboratory 2a + b Staphylococci and Streptococci

Diagnosis and Management of Skin and Soft-tissue Infections

MRSA Background. New Challenges From an Old Foe. MRSA Demographics. Comparison of Types of MRSA CA-MRSA HA-MRSA

CA-MRSA lesions: What works, what doesn t

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Methicillin Resistant Staphylococcus aureus:

Development of Drugs for Skin Infections

Bacterial skin infection

Burn Infection & Laboratory Diagnosis

Staph Cases. Case #1

Dirty Wounds. Christopher M. Ziebell, MD, FACEP

MRSA. ( Staphylococcus aureus; S. aureus ) ( community-associated )

Meropenem for all? Midge Asogan ICU Fellow (also ID AT)

Skin & Soft Tissue Infections: It's More Than Just MRSA

Skin & Soft Tissue Infections (SSTIs)

Staphylococcus aureus

Antibiotic Stewardship

Significant human pathogen. SSTI Biomaterial related infections Osteomyelitis Endocarditis Toxin mediated diseases TSST Staphylococcal enterotoxins

CLPNA Pressure Ulcers ecourse: Module 5.6 Quiz II page 1

Principles of Antimicrobial Therapy

Antimicrobial Susceptibility Patterns

Clindamycin coverage streptococcus

Community-Associated Methicillin-Resistant Staphylococcus aureus: Review of an Emerging Public Health Concern

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

GUIDE TO INFECTION CONTROL IN THE HOSPITAL

TACKLING THE MRSA EPIDEMIC

Staphylococcus Aureus

Management of Skin and Soft-Tissue Infection

Antimicrobial Resistance and Molecular Epidemiology of Staphylococcus aureus in Ghana

Objectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017

Antibacterials. Recent data on linezolid and daptomycin

Sixth Plague of Egypt. Community MRSA. Epidemiology. Basic Features of Community MRSA. Populations with CA-MRSA

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

General Approach to Infectious Diseases

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

ISPUB.COM. Animal Bites And Reconstruction. S Saraf INTRODUCTION PATIENTS AND METHODS

Symptoms of cellulitis (n=396) %

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

Excerpts Bare Minimum Microbiology Review. Staph aureus

ASSIST. PROF. Dr. Abdulameer Abdullah University of Basra, College of Nursing

Impact of a Standardized Protocol to Address Outbreak of Methicillin-resistant

Antibiotic guidelines for SKIN AND SOFT TISSUE INFECTIONS

Standing Orders for the Treatment of Outpatient Peritonitis

5/26/10. Abscess, cellulitis Recurrent skin and soft tissue infections Necrotizing fasciitis Animal bites Unusual skin and soft tissue infections

Infectious Disease Update 2017

"What's new in Infectious skin diseases"

Cellulitis and Abscess: ED Phase v 1.1

Wound Infections Lecture 20 - Dr. Gary Mumaugh

CA-MRSA: How Should We Respond to Outbreaks?

Evaluating the Role of MRSA Nasal Swabs

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

CLINICAL USE OF BETA-LACTAMS

A. Incision and drainage alone B. Incision and drainage plus oral anti-mrsa antimicrobial agent C. Oral anti-mrsa antimicrobial agent

COMMUNITY ASSOCIATED METHICILLIN-RESISTANT STAPHLOCOCCUS AUREUS A PRACTICAL GUIDE FOR PRIMARY CARE PRACTITIONERS

Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members)

Surgical Site Infections (SSIs)

What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.

Scottish Medicines Consortium

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center

Objectives. Impetigo 8/6/2013

Transcription:

Tropical infections caused by Staphylococcus aureus Michael Ellis, MD Infectious Diseases Division Uniformed Services University of the Health Sciences February 2015

Introduction Tropical Pyomyositis Cutaneous infections Prevention Bites Tropical infections caused by S. aureus Outline

S. aureus Microbiology Gram-positive cocci Grape-like clusters on gram stain Catalase positive Coagulase positive β-hemolysis on sheep blood agar MRSA Identified based on oxacillin susceptibility Can be identified using chromogenic agar Rapid identification using PCR to detect meca

Hospital-associated MRSA Risk groups Zyvox (linezolid) advertisement.

Community-associated MRSA Risk groups Household contacts of CA-MRSA infected persons Athletes Children Prison inmates Soldiers MSM IVDA N Engl J Med. 2007;357: 380.

Epidemiological and clinical characteristics Occurs in the community or <48-72h after admission Absence of traditional risk factors for MRSA Primarily cause skin and soft tissue infection (SSTI) Molecular characteristics What is CA-MRSA? Methods of description Presence of resistance and virulence factors Staphylococcal cassette chromosome mec (SCCmec) type IV Panton-Valentine leukocidin (PVL) Pulsed-field types (PFTs) USA300 Predominant strain in U.S. Clin Infect Dis. 2008;46: S368.

Community-associated MRSA Molecular characteristics PFT Location SCCmec USA300 Community Type IV USA400 Community Type IV USA100 Hospital Type II USA200 Hospital Type II Adapted from J Clin Microbiol. 2003;41:5113.

Tropical Pyomyositis

Tropical pyomyositis Pathogenesis Pyomyositis is a primary infection of skeletal muscle Does not arise from contiguous site Result of transient hematogenous seeding Usually associated with abscess formation Pathogenesis is poorly understood Associated risk factors Trauma Immunodeficiency (but most are healthy) Injection drug use Concomitant parasitic infection (e.g., toxocara) S. aureus strain virulence

25%-50% of pyomyositis associated with trauma Includes strenuous exercise Normal skeletal muscle sequesters iron and is relatively resistant to infection Fewer than 1% of S. aureus bacteremia deaths reveal skeletal muscle abscesses Damaged muscle Increased perfusion Hematoma formation Provides binding site Provides iron for bacteria Tropical pyomyositis Pathogenesis-risk factors

HIV Tropical pyomyositis Pathogenesis- risk factors Noted in African studies as significant independent risk factor T-cell dysfunction HAART toxicity Primary HIV myopathy Increased S. aureus carriage Others- DM, sickle cell, cirrhosis Injection drug use Frequent S. aureus bacteremia Increased S. aureus carriage

Accounts for 1-4% of hospital admissions in tropical countries Increasingly reported in temperate regions Likely a reflection of the emergence of CA-MRSA More common in males (1.5:1) Peak age groups 2-5 years 20-45 years Tropical pyomyositis Epidemiology Peak season in the tropics appears to be July-September

Tropical pyomyositis Microbiology Staphylococcus aureus- 90% CA-MRSA has emerged as an important pathogen Group A streptococcus- 1-5% Other pathogens Non-Group A strep Pneumococcus Gram negative enteric (e.g., E. coli) Mycobacterial (TB) Polymicrobial

Tropical pyomyositis Clinical manifestations Presents with fever and localized cramping muscle pain Usually single muscle group May be multiple in up to 20% of cases Lower extremities- but any muscle group possible Described in 3 clinical stages Stage 1 (invasive)- Stage 2 (suppurative) Most patients present during this stage Stage 3 (late)- systemic toxicity/infection

Stage 1 (invasive) Low-grade fever, mild leukocytosis Woody muscle induration Stage 2 (suppurative)- 10-21 days after initial symptoms Fever, high leukocytosis Exquisite muscle tenderness, edema, and often fluctuance Aspirate will yield purulent material Stage 3 (late)- systemic toxicity/infection Septic shock Endocarditis Pneumonia Abscesses Tropical pyomyositis Clinical manifestations

Stage 1 (invasive) Low-grade fever, mild leukocytosis Woody muscle induration Stage 2 (suppurative)- 10-21 days after initial symptoms Fever, high leukocytosis Exquisite muscle tenderness, edema, and often fluctuance Aspirate will yield purulent material Stage 3 (late)- systemic toxicity/infection Septic shock Endocarditis Pneumonia Abscesses Tropical pyomyositis Clinical manifestations

Left posterior thigh- stage 2 pyomyositis J Amer Acad Dermatol. 2004;51: 308.

CT fluid collection- stage 2 pyomyositis J Amer Acad Dermatol. 2004;51: 308.

Stage 1 (invasive) Low-grade fever, mild leukocytosis Woody muscle induration Stage 2 (suppurative)- 10-21 days after initial symptoms Fever, high leukocytosis Exquisite muscle tenderness, edema, and often fluctuance Aspirate will yield purulent material Stage 3 (late)- systemic toxicity/infection Septic shock Endocarditis Pneumonia Abscesses Tropical pyomyositis Clinical manifestations

Necrotizing pneumonia Clin Infect Dis. 2005;40: 100.

Endocarditis

Septic emboli Clin Infect Dis. 2005;40: 100.

Tropical pyomyositis Differential diagnosis Muscle contusion Cellulitis DVT Osteomyelitis Septic arthritis Neoplasm (osteosarcoma) Clostridial myonecrosis Necrotizing fasciitis Trichinosis Cysticercosis

All patients should be evaluated for endocarditis Radiography MRI (preferred), US, CT Diagnostic guided drainage prior to antibiotics Labs Leukocytosis Elevated ESR/CRP CPK usually normal Cultures Tropical pyomyositis Diagnosis Blood cultures positive in at least 10% of cases Positive in 30% of temperate pyomyositis (due to technique)

Coronal CT image of psoas abscess Infect Dis Clin NA. 2005;19: 981.

Stage 1 (invasive)- antibiotics alone may be effective Stage 2 and 3 Drainage- percutaneous or surgical Antibiotics (at least 2-3 weeks duration) Vancomycin Oxacillin Cefazolin Tropical pyomyositis Treatment Add Gram-negative and anaerobic coverage for immunocompromised

Left hip- stage 2 pyomyositis J Amer Acad Dermatol. 2004;51: 308.

Left hip- stage 2 pyomyositis- post drainage J Amer Acad Dermatol. 2004;51: 308.

Cutaneous S. aureus infections

Folliculitis Furuncles (abscesses) May be multiple Recurrence is common Outbreak settings/families Purulent cellulitis Associated with abscess/ulcer Nonpurulent cellulitis Cutaneous S. aureus infections Manifestations Contribution is unknown

Folliculitis- leg 32

Cellulitis- knee 33

Abscess-foot

Abscess- knee

Abscess- axilla

Int J Infect Dis. 2008; 12: 593.

Dermatologic conditions in travelers Epidemiology GeoSentinel Surveillance Network data 1997-2006 4742 encounters for dermatological complaints 18% of all encounters Skin lesions in returning travelers Cutaneous larvae migrans (9.8%) Insect bite (8.2%) Skin abscess (7.7%) Infected insect bite (6.8%) Int J Infect Dis. 2008; 12: 593.

Infect Dis Clin Pract. 2005;13:139.

65-year-old man who had returned from 4 wks in DRC Developed R leg swelling and pain during return trip CA-MRSA leg abscess CA-MRSA bacteremia CA-MRSA genotype, PVL+, SCCmec IV Infect Dis Clin Pract. 2005;13: 139.

Military treatment facility-baghdad 2008 66 SSTI abscesses 26 abscesses cultured 22/26 S. aureus 70% MRSA Mil Med. 2009;174: 408.

J Trauma. 2010;69: S1.

Treatment

Clin Infect Dis. 2014; epub.

SSTI management Furunculosis

Incision and drainage- most important intervention Antimicrobial therapy recommended for: Severe or extensive disease Signs/symptoms of systemic illness (Fever, tachy, leukocytosis) Rapid progression Extremes of age Comorbid conditions/immunosuppression Abscess on face, hand, groin Send specimen for culture Duration-5 days therapy SSTI management Furunculosis-outpatient Timely follow-up (24-72 hours) Clin Infect Dis. 2014; epub.

Study: 161 Pediatric patients (80% MRSA) I&D + TMP/SMX vs. I&D + placebo for 10 days Placebo cure: 95% TMP/SMX cure: 96% difference NS Ann Emerg Med. 2009.

Nonpurulent cellulitis SSTI management Cellulitis Etiology- β-hemolytic streptococci (less likely S. aureus) Empirical coverage for MRSA: Evidence of MRSA MRSA colonization Penetrating trauma Immune-compromised Systemic toxicity Timely follow-up (24-72 hours) Clin Infect Dis. 2014; epub.

Adjunctive measures Elevate and rest affected limb Treated tinea pedis Address pre-disposing conditions Extremity edema Dermatological conditions SSTI management Cellulitis Clin Infect Dis. 2014; epub.

Study: 153 patients (children and adults) nonpurulent cellulitis Cephalexin + TMP/SMX vs. Cephalexin + placebo 14d Placebo cure: 82% TMP/SMX cure: 85% difference NS No benefit to MRSA coverage Clin Infect Dis. 2013;69:

S. aureus prevention

http://www.cdc.gov/mrsa/prevent/personal.html#

http://www.cdc.gov/mrsa/prevent/personal.html#

Adhesive bandages Gauze Adhesive tape Elastic bandage Antiseptic Cotton swabs Antibacterial ointment 1% hyrocortisone cream Moleskin Thermometer SSTI Prevention Basic First Aid kit CDC Yellow Book. 2010, pg 233.

Bites Human Microbiology Aeorobic & anaerobic bacteria (oral and skin flora) Eikenella corrodens must be covered Management/prophylaxis Surgical evaluation (consider primary closure for face- specialist) Emobilize/splint Amox/clav or TMP-SMX + clindamycin Tetanus consideration Treatment of infection Obtain cultures IV antibiotics (Amp-sulbactam, Pip-taz, FQN+clinda)

Bites Dog Microbiology- 5% become infected Pasteurella spp, staph, strep, anaerobes Capnocytophaga canimorsus (asplenic, immune suppressed) Management/prophylaxis Surgical evaluation (consider form of closure) Emobilize/splint Severe- face, genitals, immune suppressed, crush Amox/clav or TMP-SMX + clindamycin (1 st dose IV) Tetanus and rabies consideration Treatment of infection Obtain cultures IV antibiotics (Amp-sulbactam, Pip-taz)

Bites Cat Microbiology- 80% become infected Pasteurella multocida, staph, strep, anaerobes Develop infection within 24 hours Management/prophylaxis- all get antibiotics! Surgical evaluation (consider form of closure) X-ray Emobilize/splint Amox/clav or doxycycline, cefuroxime (1 st dose IV) Tetanus and rabies consideration Treatment of infection (high risk for bone/joint) Obtain cultures IV antibiotics (Amp-sulbactam, FQN + metro, carbapenem)

Questions Michael Ellis, MD LTC, MC Department of Medicine Infectious Diseases Division Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814 (301) 295-2254 Michael.ellis@usuhs.mil